Tokio Marine Asset Management Co. Ltd. Acquires 3,392 Shares of Johnson & Johnson (NYSE:JNJ)

Tokio Marine Asset Management Co. Ltd. grew its stake in Johnson & Johnson (NYSE:JNJ) by 5.4% during the 3rd quarter, HoldingsChannel reports. The firm owned 66,313 shares of the company’s stock after acquiring an additional 3,392 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Johnson & Johnson were worth $10,747,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new position in shares of Johnson & Johnson in the 1st quarter valued at about $765,000. Empowered Funds LLC lifted its position in Johnson & Johnson by 46.7% in the 1st quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock valued at $16,015,000 after acquiring an additional 32,244 shares in the last quarter. O Dell Group LLC lifted its holdings in shares of Johnson & Johnson by 8.6% in the first quarter. O Dell Group LLC now owns 3,472 shares of the company’s stock valued at $549,000 after purchasing an additional 276 shares in the last quarter. QRG Capital Management Inc. boosted its holdings in Johnson & Johnson by 9.4% during the first quarter. QRG Capital Management Inc. now owns 453,858 shares of the company’s stock worth $71,796,000 after purchasing an additional 38,961 shares during the last quarter. Finally, Qsemble Capital Management LP lifted its position in Johnson & Johnson by 275.0% during the 1st quarter. Qsemble Capital Management LP now owns 19,221 shares of the company’s stock worth $3,041,000 after buying an additional 14,096 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on JNJ. Royal Bank of Canada lifted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Wells Fargo & Company lifted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, TD Cowen lowered their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $175.00.

Johnson & Johnson Price Performance

NYSE:JNJ traded down $0.23 during midday trading on Thursday, hitting $153.01. The company had a trading volume of 347,214 shares, compared to its average volume of 6,964,406. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock’s fifty day moving average price is $161.82 and its 200-day moving average price is $155.99. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a market capitalization of $368.39 billion, a PE ratio of 22.18, a P/E/G ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.66 EPS. As a group, research analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.24%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.